Coherus Oncology (CHRS) Goodwill & Intangibles (2014 - 2026)

Coherus Oncology has disclosed Goodwill & Intangibles across 13 years of filings, most recently posting $45.6 million for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $45.6 million, down 13.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.6 million (down 13.9% YoY), and the FY2025 annual result was $46.2 million, down 13.81% from the prior year.
• Goodwill & Intangibles came in at $45.6 million for Q1 2026 at Coherus Oncology, down from $46.2 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $71.7 million in Q4 2023 to a low of $3.6 million in Q1 2022.
• The 5-year median for Goodwill & Intangibles is $46.5 million (2023), against an average of $36.2 million.
• Across the five-year window, Goodwill & Intangibles soared 1108.45% in 2023 and slipped 25.15% in 2024, its largest moves.
• Coherus Oncology's Goodwill & Intangibles stood at $5.9 million in 2022, then jumped by 1108.45% to $71.7 million in 2023, then retreated by 25.15% to $53.6 million in 2024, then decreased by 13.81% to $46.2 million in 2025, then retreated by 1.35% to $45.6 million in 2026.
• The last three Goodwill & Intangibles figures came in at $45.6 million (Q1 2026), $46.2 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.